Zasocitinib
As of the edition of 20 October 2026, Zasocitinib is a small molecule: in active development; acts on TYK2.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Active, 2029
- Kind
- Small molecule
- Registered trials
- 25, 0 stopped early
- Disease areas
- Skin and connective tissue; Bones, joints and muscles; Digestive system; Infections; Pregnancy and women's health; Urinary and reproductive
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Target
| Gene | Protein | UniProt |
|---|---|---|
| TYK2 | Non-receptor tyrosine-protein kinase TYK2 | P29597 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 7 | 7 | 0 | 0 |
| Phase 2 | 8 | 2 | 6 | 0 |
| Phase 3 | 10 | 4 | 6 | 0 |
| All trials | 25 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Takeda | Lead sponsor of trials | 2021 to now |